# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Emile Griffith (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX005-SYN-TD
- Date: 2005-06-16
- Fictional facility: St. Posthumous Health Center
- Fictional author: Celeste Fairbanks-Ochieng, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Six-week review: neuropsychological testing results and the diagnosis. **S**

## History of present illness

Emile Griffith returns with his care partner for the results of his neuropsychological testing, done a week ago, and of the work-up. He has had three sessions of cognitive processing therapy; he says it is hard to write about the fight but he feels lighter after each session, and the psychologist gives him one-page summaries that his care partner reads with him between sessions. Nightmares come four or five nights a week instead of most nights. He takes sertraline 25 mg each morning without side effects. He has had no falls and no thoughts of suicide. His care partner says he repeats stories less when he is rested. He asked to hear the results with his care partner present. **S**

| Element | Detail |
|---|---|
| Neuropsychological testing | Mild cognitive impairment of frontal-subcortical type; retrieval better with cues; effort valid |
| PCL-5 | 37, from 41 at intake |
| PHQ-9 | 8; item 9 scored 0 |
| Therapy | Three sessions of cognitive processing therapy |
| Physical therapy | Evaluation booked for next week |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Neurological | Positive | Forgetfulness, better when rested; no headaches, weakness or tremor |
| Psychiatric | Positive | Nightmares four or five nights a week; less guilt; mood better; no thoughts of suicide |
| Gastrointestinal | Negative | No nausea or diarrhea |
| Musculoskeletal | Negative | No falls |

4 systems reviewed. **S**

## Current medications

- Sertraline 50 mg oral tablet, one tablet each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/78 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 73.6 kg; BMI 25.5 kg/m². All vital signs are synthetic.

PHQ-9: 8; PCL-5: 37. All results are synthetic.

## Change since baseline

- PHQ-9: 9 at baseline, 8 at this visit **S**
- PCL-5: 41 at baseline, 37 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 128/78 mmHg; pulse 68; weight 73.6 kg |
| Neurological | Unchanged: no rigidity, tremor or slowness; slightly wide-based gait |
| Mental status | Alert and engaged; asks good questions about the results and repeats the main points back correctly; no psychotic symptoms; denies thoughts of suicide |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Mild cognitive impairment, most likely due to traumatic brain injury** (G31.84). Testing, the MRI and the history fit mild cognitive impairment, most likely due to traumatic brain injury from repetitive head impacts and the severe assault, with PTSD, depressive symptoms and poor sleep adding to the difficulty. He meets the NINDS research criteria for traumatic encephalopathy syndrome; this was explained as a research label that cannot confirm the brain changes in life and does not change treatment. Alzheimer's disease is less likely given the retrieval pattern and normal hippocampi; biomarker testing was explained, and he chose not to have it now because it would not change his care (with seven microbleeds he would not be a candidate for anti-amyloid antibodies). The memory loss and confusion that brought him in are resolved into this diagnosis. **S**
   - No cholinesterase inhibitor or memantine.
   - One calendar, phone reminders and a fixed daily routine.
   - Exercise, social activity and sleep as the measures most likely to help.
   - Repeat neuropsychological testing in twelve to eighteen months, or sooner with change.
   - Card with his address and his care partner's number; shared phone location; company on unfamiliar routes; shared oversight of bills.
   - Alzheimer's Association helpline and caregiver class for his care partner.
2. **Post-traumatic stress disorder, chronic** (F43.12). Early improvement (PCL-5 37 from 41) after three therapy sessions and six weeks of sertraline 25 mg, which is well tolerated. No thoughts of suicide. **S**
   - Raise sertraline to 50 mg each morning.
   - Sodium check two to four weeks after the increase.
   - Continue weekly cognitive processing therapy.
   - Safety plan and 988 reviewed.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Cognitive testing (MoCA) | At diagnosis, then yearly, or sooner with change | Up to date | MoCA 22 at intake; next in about a year |
| Survey | Staging (CDR) and function (ADL and IADL) | At diagnosis, then yearly | Up to date | Global CDR 0.5 at two weeks; function unchanged |
| Laboratory | Reversible causes: blood count, metabolic panel, B12, TSH, depression, sleep apnea, hearing and vision | Once at diagnosis | Up to date | Completed at intake and two weeks; no reversible cause found beyond PTSD, depressive symptoms and poor sleep, which are being treated |
| Imaging | Structural brain MRI | Once at diagnosis; repeat only with an atypical course or focal change | Up to date | Done at two weeks; no repeat needed |
| Survey | Neuropsychological testing | At diagnosis when the cause or stage is unclear; repeat in 12 to 18 months or with change | Completed today | Testing a week ago reviewed today: slowed processing, reduced set-shifting and fluency, retrieval better with cues; mild cognitive impairment of frontal-subcortical type |
| Laboratory | Alzheimer's disease biomarkers (blood, CSF or amyloid PET) | When the result would change diagnosis or management | Not indicated | Explained and declined for now; would not change his care, and seven microbleeds would exclude anti-amyloid antibodies |
| Examination | Medicine review for anticholinergic, sedating and fall-risk drugs (Beers) | Every visit | Completed today | Sertraline only; no cholinesterase inhibitor started (no benefit shown in mild cognitive impairment) |
| Survey | Neuropsychiatric symptom screen (apathy, irritability, paranoia, impulsivity) | Every visit | Completed today | No apathy, irritability, paranoia or impulsive behavior |
| Survey | PHQ-9 with suicide-risk review (item 9 and structured questions) | Monthly during acute treatment; every visit during active treatment | Completed today | PHQ-9 8, item 9 scored 0; no thoughts of suicide |
| Survey | PCL-5 | Baseline, then at each chronic-care visit during treatment; response judged after 8 to 12 weeks | Completed today | PCL-5 37 (41 at intake) |
| Medication safety | Sertraline: nausea, sleep, falls, bleeding, and sodium (SSRIs can lower sodium in older adults) | Two weeks after starting and after each dose change; sodium at those points | Ordered | Well tolerated at 25 mg; raised to 50 mg today; sodium due in two to four weeks |
| Referral | Trauma-focused psychotherapy (cognitive processing therapy) | Weekly, about twelve sessions | Up to date | Three of twelve sessions done, adapted with one-page summaries |
| Examination | Fall risk (Timed Up and Go, gait and balance), STEADI | At diagnosis, yearly, and after any fall | Up to date | No falls since intake |
| Referral | Physical therapy for balance and strength | Once, after a Timed Up and Go above 12 seconds | Referred | Rebooked evaluation next week, with a reminder call |
| Self-management | Travel, money and home safety | At diagnosis and each follow-up | Completed today | Address card, shared phone location, company on unfamiliar routes and shared oversight of bills agreed |
| Survey | Care partner support and burden (Zarit Burden Interview, narrative) | At diagnosis, then every 6 to 12 months | Completed today | Zarit Burden Interview 14 (little to mild burden); helpline, caregiver class and GUIDE model explained for if dementia develops |
| Self-management | Advance care planning | At diagnosis; revisit yearly and at changes | Due | He wants to name a health care agent soon; booked for the annual wellness visit in seven weeks |
| Examination | Vascular risk factors (blood pressure, weight) | Every visit | Completed today | Blood pressure 128/78 mmHg; weight 73.6 kg |

## Goal progress

- Find the cause of the memory problems and explain it to him in a way he can take in. Outcome by 2005-06-16: Mild cognitive impairment most likely due to traumatic brain injury; explained with his care partner present, at his request, with a written summary. **S**
- A clinically meaningful fall in PTSD symptoms (PCL-5 down at least 10 points) by four months. In progress; target 2005-09-15. **S**
- Nightmares no more than about once a week, with at least six hours of sleep most nights. In progress; target 2005-10-27. **S**
- No falls, with a balance and strength program. In progress; target 2005-10-27. **S**
- Name a health care agent and record his goals of care while he can take part fully. In progress; target 2005-08-04. **S**

## Medication changes

- Stopped: Sertraline 25 mg oral tablet, one tablet each morning **S**
- Started: Sertraline 50 mg oral tablet, one tablet each morning **S**

## Guideline basis

- Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024), Alzheimer's Association (Alzheimers Dement 2025;21(1):e14337)
- National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome (2021), Neurology 2021;96(18):848-863 (Katz DI et al.)
- VA/DoD Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Disorder (2023), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, Non-Alzheimer's dementia and Depression/Bipolar/Mood Disorders monographs (2026), Aether Forge
- American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023), American Geriatrics Society (Journal of the American Geriatrics Society)
- Guiding an Improved Dementia Experience (GUIDE) Model (2024), Centers for Medicare & Medicaid Services, Innovation Center

## Follow-up

- Physical therapy evaluation next week. Annual wellness visit in seven weeks. Four-month review with PCL-5, PHQ-9 and sodium. Call the clinic or 988 at any time if thoughts of suicide arise. **S**
- Next scheduled visit 2005-08-04: subsequent annual wellness visit. **S**
